{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:04Z","timestamp":1791409924547,"version":"4.3.3"},"reference-count":149,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tomography"],"abstract":"<jats:p>Targeted radioligand therapy (RLT) is an emerging field in anticancer therapeutics with great potential across tumor types and stages of disease. While much progress has focused on agents targeting somatostatin receptors and prostate-specific membrane antigen (PSMA), the same advanced radioconjugation methods and molecular targeting have spurred the development of numerous theranostic combinations for other targets. A number of the most promising agents have progressed to clinical trials and are poised to change the landscape of positron emission tomography (PET) imaging. Here, we present recent data on some of the most important emerging molecular targeted agents with their exemplar clinical images, including agents targeting fibroblast activation protein (FAP), hypoxia markers, gastrin-releasing peptide receptors (GRPrs), and integrins. These radiopharmaceuticals share the promising characteristic of being able to image multiple types of cancer. Early clinical trials have already demonstrated superiority to 18F-fluorodeoxyglucose (18F-FDG) for some, suggesting the potential to supplant this longstanding PET radiotracer. Here, we provide a primer for practicing radiologists, particularly nuclear medicine clinicians, to understand novel PET imaging agents and their clinical applications, as well as the availability of companion targeted radiotherapeutics, the status of their regulatory approval, the potential challenges associated with their use, and the future opportunities and perspectives.<\/jats:p>","DOI":"10.3390\/tomography11080083","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:50:03Z","timestamp":1753714203000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1943-3901","authenticated-orcid":false,"given":"Maierdan","family":"Palihati","sequence":"first","affiliation":[{"name":"Department of Radiology, Columbia University Irving Medical Center, 622 W 168th St., New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeban Paul","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Capaccione","sequence":"additional","affiliation":[{"name":"Department of Radiology, Columbia University Irving Medical Center, 622 W 168th St., New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism","volume":"131","author":"Hertz","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","article-title":"Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"35","author":"Shimoni","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J. Endocrinol. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2002.20.1.189","article-title":"High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases","volume":"20","author":"Anderson","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_5","first-page":"235","article-title":"Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases","volume":"5","author":"Longo","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jama.1995.03530050068035","article-title":"Strontium 89 therapy for the palliation of pain due to osseous metastases","volume":"274","author":"Robinson","year":"1995","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jones, W., Griffiths, K., Barata, P.C., and Paller, C.J. (2020). PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061367"},{"key":"ref_9","unstructured":"(2024, December 04). 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer\u2014A Pilot Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06335069."},{"key":"ref_10","unstructured":"(2024, December 04). 68Ga-FAPI PET in Evaluation of the Patient with Known or Suspected Lung Cancer: Comparison with Standard 18F-FDG PET, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05617742."},{"key":"ref_11","unstructured":"(2024, December 04). A Phase 2, Multicenter, Single-Arm, Open-Label Non-Randomized Study of 68Ga-FAPI-46 PET in Patients with Resectable or Borderline Resectable Pancreatic Ductal Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05262855."},{"key":"ref_12","unstructured":"(2024, December 04). Initial Staging of Lobular Breast Carcinoma: Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET\/CT, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05931302."},{"key":"ref_13","unstructured":"(2024, December 04). 68Ga-FAPI-46 Positron Emission Tomography in Pancreaticobiliary Cancers: A Pharmacokinetics, Repeatability and Diagnostic Accuracy Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05957250."},{"key":"ref_14","unstructured":"(2024, December 04). 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer: A Single-center Prospective Interventional Single-arm Clinical Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05160051."},{"key":"ref_15","unstructured":"(2024, December 04). 68Ga-FAPI-46 PET\/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05903807."},{"key":"ref_16","unstructured":"(2024, December 04). Single Centre Prospective Evaluation of 68Ga-FAPI PET\/MRI in Hepatocellular Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05687747."},{"key":"ref_17","unstructured":"(2024, December 04). FAPI-CUP-Evaluating FAPI as a Novel Radiopharmaceutical Targeting Cancer-associated Fibroblasts for the Diagnosis of Patients with Cancer of Unknown Primary, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05263700."},{"key":"ref_18","unstructured":"(2024, December 04). PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05172310."},{"key":"ref_19","unstructured":"(2024, December 04). PET Biodistribution Study of 68Ga-FAPI-46 in Patients with Sarcoma: An Exploratory Biodistribution Study with Histopathology Validation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04457258."},{"key":"ref_20","unstructured":"(2024, December 04). PET Biodistribution Study of 68Ga-FAPI-46 in Patients with Prostate Cancer: A Prospective Exploratory Biodistribution Study with Histopathology Validation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04457232."},{"key":"ref_21","unstructured":"(2024, December 04). (MI-CISDIR) Multimodal Imaging with FAPI-PET\/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06540872."},{"key":"ref_22","unstructured":"(2024, December 04). 68Ga-FAPI-46 PET\/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06349512."},{"key":"ref_23","unstructured":"(2024, December 04). Evaluation of 68Ga-FAPI-46 and 18F-FDG PET\/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer with CA125 Elevation From Complete Response After Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06232122."},{"key":"ref_24","unstructured":"(2024, December 04). (PARADISE) 68Ga-FAPI PET\/CT Imaging in Chronic Inflammatory and Fibrotic Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06275477.2024."},{"key":"ref_25","unstructured":"(2024, December 04). (FAPI ILD) PET Study of 68Ga-FAPi-46 in Patients with Interstitial Lung Disease: An Exploratory Biodistribution Study with Histopathology Validation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05365802."},{"key":"ref_26","unstructured":"(2024, December 04). (HEFITEP) Pilot Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP\/TDM) in Patients with Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06160271."},{"key":"ref_27","unstructured":"(2024, December 04). (PIMAFI) FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06604260."},{"key":"ref_28","unstructured":"(2024, December 04). (LuMIERE) A Phase 1\/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04939610."},{"key":"ref_29","unstructured":"(2024, December 04). Imaging of Solid Tumors Using FAP-2286, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04621435."},{"key":"ref_30","unstructured":"(2024, December 04). Evaluating the Potential Usefulness of 68Ga-FAP-2286 PET\/CT in Patients with Various Types of Cancer and Compared with 18F-FDG PET\/CT, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05392205."},{"key":"ref_31","unstructured":"(2024, December 04). 68Ga-FAPI-RGD PET\/CT for Dual Integrin \u03b1v\u03b23 and FAP-targeted Imaging in Patients with Various Types of Cancer and Compared with 18F-FDG, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05543317."},{"key":"ref_32","unstructured":"(2024, December 04). 68Ga-FAPI-LM3 PET\/CT Imaging in Patients with FAP\/SSTR2 Positive Disease and Compared with 18F-FDG, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05873777."},{"key":"ref_33","unstructured":"(2024, December 04). Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET\/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01507428."},{"key":"ref_34","unstructured":"(2024, December 04). (MISOGLIO) Methodological Evaluation of 18F-FMISO PET-CT for Non-Operated Glioblastoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00906893."},{"key":"ref_35","unstructured":"(2024, December 04). Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) with PET and MRI, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00902577."},{"key":"ref_36","unstructured":"(2024, December 04). (FMISOPETSCS) PET with 18F-FMISO in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01868906."},{"key":"ref_37","unstructured":"(2024, December 04). Pilot Study of 18F-FMISO PET\/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects with Recurrent Glioblastoma Before and After Bevacizumab Treatment, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03573986."},{"key":"ref_38","unstructured":"(2024, December 04). Feasibility of 18F-FMISO in Assessment of Malignant Brain Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03649880."},{"key":"ref_39","unstructured":"(2024, December 04). Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-FMISO, 18F-FDG and H215O, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01246869."},{"key":"ref_40","unstructured":"(2024, December 04). A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients with Treatment-Na\u00efve High-Grade Glioma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04309552."},{"key":"ref_41","unstructured":"(2024, December 04). 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma\u2014A Feasibility and Planning Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04995185."},{"key":"ref_42","unstructured":"(2024, December 04). (MISORL) Prognostic Evaluation of 18F-FMISO PET-CT in Head and Neck Squamous Cell Carcinomas, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01235052."},{"key":"ref_43","unstructured":"(2024, December 04). Clinical Feasibility Study of Hypoxia Imaging -Guided intensity modulated radiotherapy on the Individualized Radiotherapy of Nasopharyngeal Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02089204."},{"key":"ref_44","unstructured":"(2024, December 04). (GKH-TMM) Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03547388."},{"key":"ref_45","unstructured":"(2024, December 04). Assessment of Hypoxia Before Radioembolization Treatment with 18F-FMISO PET, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06027021."},{"key":"ref_46","unstructured":"(2024, December 04). Hypoxic Changes in Hepatocellular Carcinoma Following Trans-arterial Chemo Embolization and Stereotactic Radiation: 18F-FMISO Imaging, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03303469."},{"key":"ref_47","unstructured":"(2024, December 04). A Pilot Study of Radiation De-Escalation for P16 Negative Oropharyngeal Cancer and P16-Negative or Positive Laryngeal and Hypopharyngeal Cancers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05544136."},{"key":"ref_48","unstructured":"(2024, December 04). Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study with 18F-FMISO PET\/CT, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02695628."},{"key":"ref_49","unstructured":"(2025, March 01). Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttirum-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma-Pilot Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05250895."},{"key":"ref_50","unstructured":"(2024, December 04). (HYPOXProstat) Evaluation of Hypoxia by PET with 18F-FMISO During Radiation Therapy of Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01898065."},{"key":"ref_51","unstructured":"(2024, December 04). (LuMISO) Effect of 18F-FMISO PET Imaging on Evaluation of Hypoxia Before Lu-177 PSMA Treatment for Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06433063."},{"key":"ref_52","unstructured":"(2024, December 04). A Phase 2 Study of Positron Emission Tomography Imaging with [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00559377."},{"key":"ref_53","unstructured":"(2024, December 04). Hypoxia-PET and Intensity Modulated Proton Therapy Dose Painting in Patients with Chordomas: A Pilot Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00713037."},{"key":"ref_54","unstructured":"(2024, December 04). A Phase 2 Study of PET Imaging with 18F-FMISO and 18F-FDG for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01169350."},{"key":"ref_55","unstructured":"(2025, March 01). (FIPOXY) Evaluation of the Value of 18F-FMISO PET Hypoxia Imaging in Idiopathic Pulmonary Fibrosis\u2014A Non-randomized Proof-of-concept Study Comparing Patients with Idiopathic Pulmonary Fibrosis and Healthy Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05331729."},{"key":"ref_56","unstructured":"(2024, December 04). 68Ga-RM2 PET\/MRI in the Evaluation of Patients with Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02624518."},{"key":"ref_57","unstructured":"(2024, December 04). A Phase II Study of 68Ga-RM2 for PET\/CT of GRPr Expression in Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02559115."},{"key":"ref_58","unstructured":"(2024, December 04). 68Ga-RM2 PET\/CT for Detection of Regional Nodal and Distant Metastases in Patients with Intermediate and High-Risk Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03113617."},{"key":"ref_59","unstructured":"(2024, December 04). Evaluation of the LightPath\u00ae Imaging System and the PET Tracer 68Ga-RM2 in Wide Local Excision for Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03731026."},{"key":"ref_60","unstructured":"(2024, December 04). (PROSTATEP) Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET\/CT Versus 68Ga-PSMA-617 PET\/CT in Patients Diagnosed with Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03606837."},{"key":"ref_61","unstructured":"(2024, December 04). Phase II Prospective Monocentric Study on Prostate Cancer Restaging by Using PET\/MR with Innovative Radiotracers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05806853."},{"key":"ref_62","unstructured":"(2024, December 04). A Pilot Study of 68Ga-RM2 PET\/MRI in the Evaluation of Patients with Estrogen Receptor-Positive Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03831711."},{"key":"ref_63","unstructured":"(2024, December 04). (SABRE) 64Cu-SAR-BBN PET: A Phase 2 Study of Participants with PSMA-negative Biochemical Recurrence of Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05407311."},{"key":"ref_64","unstructured":"(2024, December 04). (BOP) Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men with Negative PSMA PET in Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05613842."},{"key":"ref_65","unstructured":"(2024, December 04). (COMBAT) A Phase I\/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy with 177Lu-PSMA-617, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05633160."},{"key":"ref_66","unstructured":"(2024, December 04). (MITIGATE-NeoBOMB1) A Phase I\/IIa Study to Evaluate Safety, Biodistribution, Dosimetry, and Preliminary Diagnostic Performance of 68Ga-NeoBOMB1 in Patients with Advanced TKI-treated Gastrointestinal Stromal Tumor Using PET\/CT, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02931929."},{"key":"ref_67","unstructured":"(2024, December 04). (NeoFIND) Phase II Study of Preliminary Diagnostic Performance of 68Ga-NeoBOMB1 in Adult Patients with Malignancies Known to Overexpress Gastrin-Releasing Peptide Receptor, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03724253."},{"key":"ref_68","unstructured":"(2024, December 04). 68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET\/MRI in the Evaluation of Patients with Biochemical Recurrence of Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03698370."},{"key":"ref_69","unstructured":"(2024, December 04). (NeoRay) A Phase I\/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of 177Lu-NeoB Administered in Patients with Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03872778."},{"key":"ref_70","unstructured":"(2024, December 04). A Phase I\/II, Open-label, Multi-center Trial of 177Lu-NeoB in Combination with Capecitabine in Adult Patients with Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination with a CDK4\/6 Inhibitor, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06247995."},{"key":"ref_71","unstructured":"(2024, December 04). A Phase Ib Dose Finding Study Assessing Safety and Activity of 177Lu-NeoB in Combination with Ribociclib and Fulvestrant in Participants with Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination with a CDK4\/6 Inhibitor for Advanced Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05870579."},{"key":"ref_72","unstructured":"(2024, December 04). Phase Ib Dose Finding Study Assessing Safety and Activity of 177Lu-NeoB in Combination with Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05739942."},{"key":"ref_73","unstructured":"(2024, December 04). Assessment of the Diagnostic and Theranostic Potential of 68Ga-Bombesin PET\/CT (NeoB) Imaging for Staging of ER\/PR + HER2- Breast Cancer Patients with Metastatic Disease: Comparison to Conventional Imaging, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05889728."},{"key":"ref_74","unstructured":"(2024, December 04). (NEPC) A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study with PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06379217."},{"key":"ref_75","unstructured":"(2024, December 04). A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumors and Angiogenesis Via the Expression of \u03b1\u03bd\u03b23\/5 Integrin Receptors by 18F-AH-111585 PET Imaging, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00565721."},{"key":"ref_76","unstructured":"(2024, December 04). A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of 18F-AH111585 Injection, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00918281."},{"key":"ref_77","unstructured":"(2024, December 04). (PAZPET-1) Phase 1b Exploratory Study of 18F-Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy with the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01608009."},{"key":"ref_78","unstructured":"(2024, December 04). (GRGDG) Diagnostic Performance and Evaluation Efficacy of Brain 68Ga-BNOTA-PRGD2 PET\/CT in Pre-surgery Glioma Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01801371."},{"key":"ref_79","unstructured":"(2024, December 04). (GRGDLC) Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-BNOTA-PRGD2 in Healthy Volunteers and Lung Cancer Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01527058."},{"key":"ref_80","unstructured":"(2024, December 04). Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06638034."},{"key":"ref_81","unstructured":"(2024, December 04). A Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and \u03b1v\u03b23 Positive Tumors 68Ga-RM26-RGD PET\/CT Imaging in the GRPR and \u03b1v\u03b23 Positive Tumor Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06632860."},{"key":"ref_82","unstructured":"(2024, December 04). 68Ga-RM26-RGD PET\/CT Imaging in the GRPR and \u03b1v\u03b23 Positive Tumor Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05549024."},{"key":"ref_83","unstructured":"(2024, December 04). Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients with Integrin \u03b1V\u03b23 Positive Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05013086."},{"key":"ref_84","unstructured":"(2024, December 04). Phase 1\/2 18F-FPPRGD2 PET\/CT or PET\/MRI Imaging of \u03b1v\u03b23 Integrins Expression as a Biomarker of Angiogenesis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01806675."},{"key":"ref_85","unstructured":"(2024, December 04). Biodistribution and Safety of the PET Probes 18F-FPRGD2 and 18F-FPPRGD2, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01383135."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1523-1747.2003.12035.x","article-title":"Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors","volume":"120","author":"Huber","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models","volume":"61","author":"Watabe","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"Npj Imaging"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0895-4356(03)00177-X","article-title":"The diagnostic odds ratio: A single indicator of test performance","volume":"56","author":"Glas","year":"2003","journal-title":"J. Clin. Epidemiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/RLU.0000000000004438","article-title":"Comparison of the Detection Performance Between FAP and FDG PET\/CT in Various Cancers: A Systemic Review and Meta-analysis","volume":"48","author":"Chang","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_95","first-page":"2271","article-title":"177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1\/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)","volume":"63","author":"Goenka","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using (68)Ga-FAP-2286: Comparison with (18)F-FDG and (68)Ga-FAPI-46 in a Single-Center, Prospective Study","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Lindner, T., Giesel, F.L., Kratochwil, C., and Serfling, S.E. (2021). Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers, 13.","DOI":"10.3390\/cancers13225744"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1074\/mcp.M112.018325","article-title":"Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies","volume":"12","author":"Ren","year":"2013","journal-title":"Mol. Cell Proteom."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-21-2394","article-title":"(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition","volume":"28","author":"Reeves","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_100","unstructured":"(2024, December 04). A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02498613."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/radiation1010004","article-title":"Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: A Potent GRPR Antagonist in Prostate Carcinoma Patients","volume":"1","author":"Haendeler","year":"2021","journal-title":"Radiation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(24)00069-X","article-title":"(68)Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: A single-centre, single-arm, phase 2\/3 imaging trial","volume":"25","author":"Duan","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-020-00652-y","article-title":"Voxel-based comparison of [(68)Ga]Ga-RM2-PET\/CT and [(68)Ga]Ga-PSMA-11-PET\/CT with histopathology for diagnosis of primary prostate cancer","volume":"10","author":"Fassbender","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., Brown, L., Dear, R., Chan, L., and Sharma, S. (2022). (64)Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen\/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070772"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: A radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Nordquist, L.T., Lengyelova, E., Almaguel, F., Mancini, B.R., Song, H., Armstrong, A.J., Zurita, A.J., Anderson, M., Parker, M., and Miller, R.M. (2024). COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. J. Clin. Oncol., 42.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS247"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","article-title":"MITIGATE-NeoBOMB1, a Phase I\/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients","volume":"61","author":"Gruber","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ceb.2011.08.005","article-title":"Mechanisms of integrin activation and trafficking","volume":"23","author":"Margadant","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Haubner, R., Maschauer, S., and Prante, O. (2014). PET radiopharmaceuticals for imaging integrin expression: Tracers in clinical studies and recent developments. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/871609"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41556-018-0223-z","article-title":"Integrin trafficking in cells and tissues","volume":"21","author":"Icha","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sleeboom, J.J.F., van Tienderen, G.S., Schenke-Layland, K., van der Laan, L.J.W., Khalil, A.A., and Verstegen, M.M.A. (2024). The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets. Sci. Transl. Med., 16.","DOI":"10.1126\/scitranslmed.adg3840"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.107.049452","article-title":"Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients","volume":"49","author":"Kenny","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_117","first-page":"13","article-title":"Development and in vitro fatigue testing of a new bloodpump","volume":"1","author":"Zartnack","year":"1983","journal-title":"Life Support. Syst."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00259-019-04532-z","article-title":"[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant\/refractory ovarian cancer","volume":"47","author":"Sharma","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00259-021-05333-z","article-title":"(18)F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: Comparison with (18)F-FDG","volume":"49","author":"Wu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2174\/138945009788680374","article-title":"Defining the role of integrin alphavbeta6 in cancer","volume":"10","author":"Bandyopadhyay","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Kimura, R.H., Iagaru, A., and Guo, H.H. (2023). Mini review of first-in-human integrin \u03b1v\u03b26 PET tracers. Front. Nucl. Med., 3.","DOI":"10.3389\/fnume.2023.1271208"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-18-2665","article-title":"Preclinical Development and First-in-Human Imaging of the Integrin alpha(v)beta(6) with [(18)F]alpha(v)beta(6)-Binding Peptide in Metastatic Carcinoma","volume":"25","author":"Hausner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1021\/acs.molpharmaceut.1c00632","article-title":"Evaluation of Copper-64-Labeled alpha(v)beta(6)-Targeting Peptides: Addition of an Albumin Binding Moiety to Improve Pharmacokinetics","volume":"18","author":"Ganguly","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-021-05559-x","article-title":"PET\/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the \u201cCancer Integrin\u201d alphavbeta6 with Ga-68-Trivehexin","volume":"49","author":"Quigley","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_126","first-page":"754","article-title":"Biokinetics and Dosimetry of (177)Lu-Pentixather","volume":"63","author":"Hanscheid","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT with [(68) Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.116.178970","article-title":"Safety, Dosimetry, and Tumor Detection Ability of (68)Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging","volume":"58","author":"Skovgaard","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.121.263177","article-title":"Prospective Phase II Trial of Prognostication by (68)Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy","volume":"63","author":"Carlsen","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.121.262866","article-title":"Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET\/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG PET\/CT: A Single-Center Prospective Study","volume":"63","author":"Risor","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaoncol.2020.0334","article-title":"Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial","volume":"6","author":"McDonald","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-19-3484","article-title":"Safety and Feasibility of PARP1\/2 Imaging with (18)F-PARPi in Patients with Head and Neck Cancer","volume":"26","author":"Schoder","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1148\/radiol.2016161929","article-title":"PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies","volume":"282","author":"Michel","year":"2017","journal-title":"Radiology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2967\/jnumed.117.193847","article-title":"(177)Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results","volume":"59","author":"Baum","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET\/CT Imaging of Advanced Urothelial Carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2326-6066.CIR-21-0405","article-title":"Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054","volume":"10","author":"Tavare","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting","volume":"61","author":"Postow","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","article-title":"Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: A phase 1\/2 trial","volume":"28","author":"Giesen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2967\/jnumed.119.240895","article-title":"Quantification of PD-L1 Expression with (18)F-BMS-986192 PET\/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer","volume":"61","author":"Huisman","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Hegi-Johnson, F., Rudd, S.E., Wichmann, C., Akhurst, T., Roselt, P., Trinh, J., John, T., Devereux, L., Donnelly, P.S., and Hicks, R. (2022). ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: A phase 0\/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET\/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open, 12.","DOI":"10.1136\/bmjopen-2021-056708"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1007\/s00259-022-05876-9","article-title":"Preclinical and first-in-human evaluation of (18)F-labeled D-peptide antagonist for PD-L1 status imaging with PET","volume":"49","author":"Zhou","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.nucmedbio.2012.01.010","article-title":"Tryptophan metabolism in breast cancers: Molecular imaging and immunohistochemistry studies","volume":"39","author":"Juhasz","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Singnurkar, A., Poon, R., and Metser, U. (2024). Head-to-Head Comparison of the Diagnostic Performance of FDG PET\/CT and FDG PET\/MRI in Patients with Cancer: A Systematic Review and Meta-Analysis. AJR Am. J. Roentgenol., 223.","DOI":"10.2214\/AJR.24.31519"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: A roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/8\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:27Z","timestamp":1760033847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/8\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":149,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["tomography11080083"],"URL":"https:\/\/doi.org\/10.3390\/tomography11080083","relation":{},"ISSN":["2379-139X"],"issn-type":[{"value":"2379-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}